Skip to main content

Compare Stocks

Date Range: 

 Forty SevenBiohaven PharmaceuticalSage TherapeuticsHutchison China MediTechEmergent BioSolutions
SymbolNASDAQ:FTSVNYSE:BHVNNASDAQ:SAGENASDAQ:HCMNYSE:EBS
Price Information
Current Price$95.51$69.85$70.86$25.81$62.00
52 Week RangeN/ABuyBuyBuyBuy
MarketRank™
Overall Score1.02.01.61.42.2
Analysis Score0.04.54.33.53.3
Community Score2.62.43.12.72.7
Dividend Score0.00.00.00.00.0
Ownership Score2.52.50.00.01.7
Earnings & Valuation Score0.00.60.60.63.1
Analyst Ratings
Consensus RecommendationN/ABuyBuyBuyBuy
Consensus Price TargetN/A$99.50$89.87$40.00$99.20
% Upside from Price TargetN/A42.45% upside26.82% upside54.98% upside60.00% upside
Trade Information
Market Cap$4.60 billion$4.55 billion$4.14 billion$3.84 billion$3.32 billion
Beta0.41.092.231.121.26
Average Volume1,606,836607,830493,731237,881744,043
Sales & Book Value
Annual Revenue$15.68 millionN/A$6.87 million$204.89 million$1.11 billion
Price / Sales293.33N/A603.1918.763.00
CashflowN/AN/AN/AN/A$2.97 per share
Price / CashN/AN/AN/AN/A20.89
Book Value$7.52 per share($0.14) per share$18.23 per share$2.35 per share$21.08 per share
Price / Book12.70N/A3.8910.982.94
Profitability
Net Income$-87,620,000.00$-528,800,000.00$-680,240,000.00$-106,020,000.00$54.50 million
EPS($2.34)($10.91)($13.38)($0.80)$2.91
Trailing P/E RatioN/AN/AN/AN/A19.94
Forward P/E RatioN/AN/AN/AN/A6.73
P/E GrowthN/AN/AN/AN/AN/A
Net MarginsN/AN/A-7,706.84%N/A12.50%
Return on Equity (ROE)-50.38%-1,091.41%-63.81%N/A26.68%
Return on Assets (ROA)-44.35%-120.85%-56.64%N/A12.70%
Dividend
Annual PayoutN/AN/AN/AN/AN/A
Dividend YieldN/AN/AN/AN/AN/A
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/AN/AN/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt
Debt-to-Equity RatioN/AN/AN/A0.07%0.68%
Current Ratio14.81%3.26%11.71%3.14%3.20%
Quick Ratio14.81%3.17%11.71%3.01%2.30%
Ownership Information
Institutional Ownership Percentage71.77%99.37%N/A33.45%80.23%
Insider Ownership Percentage37.40%19.10%4.80%N/A14.10%
Miscellaneous
Employees578252981,2802,200
Shares Outstanding48.16 million65.07 million58.48 million148.90 million53.59 million
Next Earnings DateN/A8/9/2021 (Estimated)8/9/2021 (Estimated)N/A7/29/2021 (Estimated)
OptionableNot OptionableOptionableOptionableNot OptionableOptionable
SourceHeadline
Kessler Topaz Meltzer & Check, LLP Files a Shareholder Class Action Lawsuit Against Emergent BioSolutions Inc. (NYSE: EBS) for Violations of Federal Securities Laws With ...Kessler Topaz Meltzer & Check, LLP Files a Shareholder Class Action Lawsuit Against Emergent BioSolutions Inc. (NYSE: EBS) for Violations of Federal Securities Laws With ...
businesswire.com - May 15 at 12:28 AM
Emergent BioSolutions setbacks cause J&J vaccine supply to dwindleEmergent BioSolutions setbacks cause J&J vaccine supply to dwindle
bizjournals.com - May 14 at 2:00 PM
Emergent (EBS) Issues Plan to Resume Bayview Facility OperationEmergent (EBS) Issues Plan to Resume Bayview Facility Operation
nasdaq.com - May 14 at 2:00 PM
Head to Head Survey: Emergent BioSolutions (NYSE:EBS) and Agios Pharmaceuticals (NASDAQ:AGIO)Head to Head Survey: Emergent BioSolutions (NYSE:EBS) and Agios Pharmaceuticals (NASDAQ:AGIO)
americanbankingnews.com - May 14 at 10:24 AM
LAWSUIT FILED: Emergent BioSolutions Inc. Sued for Violations of the Federal Securities Laws; Investors Should Contact Block & Leviton LLPLAWSUIT FILED: Emergent BioSolutions Inc. Sued for Violations of the Federal Securities Laws; Investors Should Contact Block & Leviton LLP
morningstar.com - May 13 at 2:44 PM
EBS INVESTORS ACT NOW: Contact HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, to Recover Losses Due to Alleged Securities FraudEBS INVESTORS ACT NOW: Contact HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, to Recover Losses Due to Alleged Securities Fraud
finance.yahoo.com - May 13 at 2:44 PM
Important Deadline Reminder: Kessler Topaz Meltzer & Check, LLP Reminds Emergent BioSolutions Inc. Investors of Securities Fraud Class Action LawsuitImportant Deadline Reminder: Kessler Topaz Meltzer & Check, LLP Reminds Emergent BioSolutions Inc. Investors of Securities Fraud Class Action Lawsuit
prnewswire.com - May 12 at 7:15 PM
Important Deadline Reminder:  Kessler Topaz Meltzer & Check, LLP Reminds Emergent BioSolutions Inc. Investors of Securities Fraud Class Action LawsuitImportant Deadline Reminder: Kessler Topaz Meltzer & Check, LLP Reminds Emergent BioSolutions Inc. Investors of Securities Fraud Class Action Lawsuit
finance.yahoo.com - May 12 at 7:15 PM
ROSEN, RESPECTED INVESTOR COUNSEL, Encourages Emergent BioSolutions Inc. Investors with Losses to Secure Counsel Before Important June 18 Deadline in Securities Class Action - EBSROSEN, RESPECTED INVESTOR COUNSEL, Encourages Emergent BioSolutions Inc. Investors with Losses to Secure Counsel Before Important June 18 Deadline in Securities Class Action - EBS
finance.yahoo.com - May 12 at 7:15 PM
SHAREHOLDER ALERT: Lowey Dannenberg, P.C., Investigates Claims on Behalf of Investors of Emergent BioSolutions Inc. (EBS) and Encourages Investors With More Than $300,000 in Losses to Contact the FirmSHAREHOLDER ALERT: Lowey Dannenberg, P.C., Investigates Claims on Behalf of Investors of Emergent BioSolutions Inc. (EBS) and Encourages Investors With More Than $300,000 in Losses to Contact the Firm
finance.yahoo.com - May 12 at 2:15 PM
EBS Reminder: Kessler Topaz Meltzer & Check, LLP - Deadline Reminder for Emergent BioSolutions Inc. InvestorsEBS Reminder: Kessler Topaz Meltzer & Check, LLP - Deadline Reminder for Emergent BioSolutions Inc. Investors
ca.finance.yahoo.com - May 11 at 7:47 PM
CLASS ACTION UPDATE for EBS, GOEV, SOS: HAGENS BERMAN Updates Investors on Securities Class Actions, Advises Investors with Losses to Contact the Firm NowCLASS ACTION UPDATE for EBS, GOEV, SOS: HAGENS BERMAN Updates Investors on Securities Class Actions, Advises Investors with Losses to Contact the Firm Now
finance.yahoo.com - May 11 at 2:47 PM
Emergent BioSolutions (NYSE:EBS) Releases Q2 2021 Earnings GuidanceEmergent BioSolutions (NYSE:EBS) Releases Q2 2021 Earnings Guidance
americanbankingnews.com - May 11 at 2:34 PM
Emergent BioSolutions (NYSE:EBS) Sets New 12-Month Low at $55.12Emergent BioSolutions (NYSE:EBS) Sets New 12-Month Low at $55.12
americanbankingnews.com - May 11 at 10:37 AM
Emergent BioSolutions (NYSE:EBS) Receives Hold Rating from ArgusEmergent BioSolutions (NYSE:EBS) Receives Hold Rating from Argus
americanbankingnews.com - May 11 at 9:42 AM
Emergent BioSolutions (NYSE:EBS) Rating Reiterated by ArgusEmergent BioSolutions (NYSE:EBS) Rating Reiterated by Argus
marketbeat.com - May 11 at 8:49 AM
CLASS ACTION ALERT: Kessler Topaz Meltzer & Check, LLP Announces Class Action Lawsuit Has Been Filed Against Emergent BioSolutions Inc.CLASS ACTION ALERT: Kessler Topaz Meltzer & Check, LLP Announces Class Action Lawsuit Has Been Filed Against Emergent BioSolutions Inc.
ca.finance.yahoo.com - May 10 at 3:27 PM
Kessler Topaz Meltzer & Check, LLP: Securities Fraud Class Action Filed Against Emergent BioSolutions Inc.Kessler Topaz Meltzer & Check, LLP: Securities Fraud Class Action Filed Against Emergent BioSolutions Inc.
uk.finance.yahoo.com - May 8 at 7:53 PM
HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Emergent BioSolutions (EBS) Investors with $100k+ Losses to Contact its Attorneys Now, Securities Class Action FiledHAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Emergent BioSolutions (EBS) Investors with $100k+ Losses to Contact its Attorneys Now, Securities Class Action Filed
finance.yahoo.com - May 8 at 2:52 PM
SHAREHOLDER ALERT: CLAIMSFILER REMINDS CCXI, EBS, GOEV, RMO, INVESTORS of Lead Plaintiff ...SHAREHOLDER ALERT: CLAIMSFILER REMINDS CCXI, EBS, GOEV, RMO, INVESTORS of Lead Plaintiff ...
apnews.com - May 7 at 11:27 PM
SHAREHOLDER ALERT: CLAIMSFILER REMINDS CCXI, EBS, GOEV, RMO, INVESTORS of Lead Plaintiff ...SHAREHOLDER ALERT: CLAIMSFILER REMINDS CCXI, EBS, GOEV, RMO, INVESTORS of Lead Plaintiff ...
apnews.com - May 7 at 11:27 PM
Emergent BioSolutions Inc. Reminder:  Kessler Topaz Meltzer & Check, LLP Reminds Investors of Securities Fraud Class Action Lawsuit Filed Against Emergent BioSolutions Inc.Emergent BioSolutions Inc. Reminder: Kessler Topaz Meltzer & Check, LLP Reminds Investors of Securities Fraud Class Action Lawsuit Filed Against Emergent BioSolutions Inc.
prnewswire.com - May 7 at 6:50 PM
Lawsuits Filed Against SOS, CAN and EBS - Jakubowitz Law Pursues Shareholders ClaimsLawsuits Filed Against SOS, CAN and EBS - Jakubowitz Law Pursues Shareholders Claims
finance.yahoo.com - May 7 at 1:21 PM
Important Investor Reminder: Kessler Topaz Meltzer & Check, LLP Reminds Emergent BioSolutions Inc. Investors of Deadline in Securities Fraud Class Action LawsuitImportant Investor Reminder: Kessler Topaz Meltzer & Check, LLP Reminds Emergent BioSolutions Inc. Investors of Deadline in Securities Fraud Class Action Lawsuit
feeds.benzinga.com - May 6 at 3:54 PM
Emergent BioSolutions (NYSE:EBS) Price Target Lowered to $92.00 at Chardan CapitalEmergent BioSolutions (NYSE:EBS) Price Target Lowered to $92.00 at Chardan Capital
americanbankingnews.com - May 6 at 3:38 PM
SHAREHOLDER ALERT: FGEN EBS PTON: The Law Offices of Vincent Wong Reminds Investors of Important Class Action DeadlinesSHAREHOLDER ALERT: FGEN EBS PTON: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines
finance.yahoo.com - May 6 at 12:18 PM
Chardan Capital Lowers Emergent BioSolutions (NYSE:EBS) Price Target to $92.00Chardan Capital Lowers Emergent BioSolutions (NYSE:EBS) Price Target to $92.00
marketbeat.com - May 6 at 10:08 AM
Emergent BioSolutions (NYSE:EBS) Given New $92.00 Price Target at Chardan CapitalEmergent BioSolutions (NYSE:EBS) Given New $92.00 Price Target at Chardan Capital
marketbeat.com - April 30 at 11:04 AM
DateCompanyBrokerageAction
3/4/2020Forty SevenMizuhoDowngrade
3/3/2020Forty SevenGuggenheimDowngrade
3/3/2020Forty SevenSunTrust BanksDowngrade
3/3/2020Forty SevenMorgan StanleyDowngrade
3/3/2020Forty SevenCanaccord GenuityDowngrade
3/2/2020Forty SevenRoth CapitalDowngrade
3/2/2020Forty SevenHC WainwrightDowngrade
1/17/2020Forty SevenOppenheimerBoost Price Target
12/10/2019Forty SevenCitigroupBoost Price Target
12/10/2019Forty SevenBTIG ResearchReiterated Rating
12/5/2019Forty SevenCredit Suisse GroupReiterated Rating
5/12/2021Biohaven PharmaceuticalSVB LeerinkLower Price Target
3/17/2021Biohaven PharmaceuticalUBS GroupInitiated Coverage
3/1/2021Biohaven PharmaceuticalPiper SandlerBoost Price Target
2/5/2021Biohaven PharmaceuticalWilliam BlairReiterated Rating
12/29/2020Biohaven PharmaceuticalCantor FitzgeraldBoost Price Target
10/13/2020Biohaven PharmaceuticalWedbushBoost Price Target
2/1/2021Sage TherapeuticsRaymond JamesInitiated Coverage
1/22/2021Sage TherapeuticsBMO Capital MarketsDowngrade
1/4/2021Sage TherapeuticsRoyal Bank of CanadaDowngrade
12/1/2020Sage TherapeuticsCitigroup Inc. 3% Minimum Coupon Principal Protected Based Upon RussellLower Price Target
12/1/2020Sage TherapeuticsTruistBoost Price Target
12/1/2020Sage TherapeuticsSmith Barney CitigroupLower Price Target
10/2/2020Hutchison China MediTechDeutsche Bank AktiengesellschaftInitiated Coverage
2/20/2020Hutchison China MediTechThe Goldman Sachs GroupInitiated Coverage
11/19/2019Hutchison China MediTechCLSAInitiated Coverage
10/23/2019Hutchison China MediTechBank of AmericaInitiated Coverage
7/5/2019Hutchison China MediTechMacquarieInitiated Coverage
3/27/2019Hutchison China MediTechHSBCInitiated Coverage
5/11/2021Emergent BioSolutionsArgusReiterated Rating
5/6/2021Emergent BioSolutionsChardan CapitalLower Price Target
5/5/2021Emergent BioSolutionsWells Fargo & CompanyLower Price Target
4/30/2021Emergent BioSolutionsBenchmarkLower Price Target
9/14/2020Emergent BioSolutionsJPMorgan Chase & Co.Initiated Coverage
(Data available from 5/15/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.